泌尿道感染的全球市場:預測(2022年～2028年)

全球泌尿道感染的市場規模在預測期間(2022年～2028年)內預計將以4.8％的年複合成長率增長。糖尿病和腎結石發病率的上升、更有效的組合藥物的出現以及老年人口的增加正在推動尿路感染市場的增長。

本報告提供全球泌尿道感染市場相關調查分析，提供市場概要，競爭情形，市場分析，企業簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

• 調查範圍
• 分析師的洞察和目前市場趨勢
• 規則

第3章 競爭情形

• 主要企業分析
  • 概要
  • 財務分析
  • SWOT分析
• 主要策略分析
• COVID-19對主要企業帶來的影響

第4章 市場決策要素

• 促進因素
• 阻礙因素
• 機會

第5章 市場區隔

• 全球泌尿道感染市場:檢驗各類型
  • 生物化學的泌尿道感染
  • 顯微鏡的泌尿道感染
  • 流式細胞技術泌尿道感染
• 全球泌尿道感染市場:各適應症
  • 併發症的泌尿道感染
  • 非併發症的泌尿道感染
  • 神經原因性膀胱炎
• 全球泌尿道感染市場:各終端用戶
  • 醫院和診所
  • 居家醫療

第6章 地區分析

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 西班牙
  • 法國
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 全球其他地區

第7章 企業簡介

• Acon Laboratories, Inc.
• ARKRAY Group
• AstraZeneca PLC
• Bayer AG
• Danaher Corp.
• Becton, Dickinson and Co.
• Biomerieux S.A.
• Bio-Rad Laboratories Inc.
• Biotronik SE & Co. KG
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
• Siemens AG
• Shionogi & Co., Ltd.
• Sysmex Europe GmbH.
• Teva Pharmaceutical Industries Ltd.
• Watson's Personal Care Pte. Ltd.

Global Urinary Tract Infection Market Size, Share & Trends Analysis Report By Test Type (Biochemical Urinary Tract Infection, Microscopic Urinary Tract Infection, Flow Cytometric Urinary Tract Infection) By Indication (Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection, Neurogenic Bladder Infections), End-User (Hospitals & Clinics, and Home Healthcare) Forecast Period 2021-2027

The global urinary tract infection market is anticipated to grow at a CAGR of around 4.8% during the forecast period. Urinary tract infections affect the urinary tract of a person also causing bladder (cystitis), urethra (urethritis), or kidney infections. Urinary tract infections are developed when microbes enter the urinary tract and result in infection. Bacteria are considered to be the most common cause of urinary tract infection, coli bacteria that live in the bowel causes most urinary tract infections. The number of cases of urinary tract infection increases as the incidence of diabetes and kidney stones rises, which in turn raises drug demand, driving the global urinary tract infection market. Moreover, the demand for urinary tract infections treatment drugs is expected to grow due to the introduction of more effective combination drugs and the growing geriatric population.

With an increase in the number of cases of adverse drug reactions (ADRs) being identified across the globe, there is a lack of public awareness for drug adoption, which is a major restraint for the urinary tract infection industry. Further, COVID-19 has also a certain positive impact on the market such as some of the common comorbidity seen in COVID-19 patients in diabetes, hypertension, and chronic lung disease. Not only respiratory illness however COVID-19 may also damage certain organs systems of the body along with human urinal systems. Therefore COVID-19 may result in the cause of bladder dysfunction and further projected to propel the demand for drugs during the forecast period.

Segmental Outlook

The global urinary tract infection market is segmented based on test type, indication, and end-user. On the basis of test type, the market is segmented into biochemical urinary tract infection, microscopic urinary tract infection, and flow cytometric urinary tract infection. Based on indication, the market is segmented into complicated urinary tract infection, uncomplicated urinary tract infection, neurogenic bladder infections. Further on the basis of end-user, the market is segmented into hospitals & clinics, and home healthcare.

Global Urinary Tract Infection Market Share by Indication, 2020 (%)

Global Urinary Tract Infection Market Share by Indication

Complicated urinary tract infection projected to hold a significant share in the global urinary tract infection market

Among indication, the complicated urinary tract infection segment is projected to have a considerable share in the global market. Due to the rise in drug-resistant bacteria and the overuse of antibiotics, the prevalence of complicated urinary tract infection is projected to rise in the future. Quinolones are prescribed by most doctors to treat complex urinary tract infection cases. Cephalosporin is the second most prescribed antibiotic for complicated urinary tract infections. Complicated urinary tract infections have a higher chance of medication failure, requiring longer antibiotic courses and, in certain cases, further testing. Complicated urinary tract infections may occur in males, pregnant women, in immunocompromised patients, or the elderly, due to atypical bacteria, after instrumentation or in combination with medical equipment such as urinary catheters, in renal transplant patients, and patients with impaired renal function. Overall, the prevalence of complicated urinary tract infection is expected to rise during the forecast period, owing to rising bacterial resistance in urinary tract infection cases and a higher recurrence rate.

Regional Outlooks

The global urinary tract infection market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Due to a high prevalence rate of urinary tract infections, North America is projected to have a significant share in the global market. Furthermore, the region has a well-developed healthcare system, which contributes to the market share. According to National Center for Biotechnology Information in 2019, in the US the prevalence of urinary tract infection in women above 65 years is approximately 20.0% as compared to 11.0% prevalence in the overall population, therefore almost 50.0% to 60.0% of adult women will have at least one urinary tract infection in their life.

Global Urinary Tract Infection Market Growth, by Region 2021-2027

Global Urinary Tract Infection Market Share by region

Asia-Pacific is projected to grow significantly in the global urinary tract infection market during the forecast period.

Geographically, Asia-Pacific estimated to have considerable CAGR in the global urinary tract infection market during the forecast period. The growth is attributed to the increasing prevalence of chronic diseases such as diabetes and renal failure in major countries such as China, India, and. The other factors being increasing large number of drug manufacturers for the disease, increasing awareness among the people regarding the treatment options for urinary tract infections, rise inpatient population. Furthermore, the demand for urinary tract infection treatment drugs in private hospitals and further projected to provide ample opportunity to the market growth.

Market Players Outlook

The key players of the urinary tract infection market include AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE & Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in November 2019, Shionogi & Co., Ltd. got the US FDSA approval for its Fetroja that is an antibacterial drug for treatment for patients 18 years and above with complicated tract infections including kidney infections. This approval will be providing an additional treatment option for patients with complicated urinary tract infection who have limited and no treatment options.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Urinary Tract Infection market

Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

• 1.1. Research Methods and Tools
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Urinary Tract Infection Industry
• Recovery Scenario of Global Urinary Tract Infection Industry
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion
• 2.3. Regulations

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
• 3.2. Key Strategy Analysis
• 3.3. Impact of COVID-19 on key players

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Urinary Tract Infection Market by Test Type
  • 5.1.1. Biochemical Urinary Tract Infection
  • 5.1.2. Microscopic Urinary Tract Infection
  • 5.1.3. Flow Cytometric Urinary Tract Infection
• 5.2. Global Urinary Tract Infection market by Indication
  • 5.2.1. Complicated Urinary Tract Infection
  • 5.2.2. Uncomplicated Urinary Tract Infection
  • 5.2.3. Neurogenic Bladder Infections
• 5.3. Global Urinary Tract Infection market by End-User
  • 5.3.1. Hospitals and Clinics
  • 5.3.2. Home Healthcare

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korea
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. Acon Laboratories, Inc.
• 7.2. ARKRAY Group
• 7.3. AstraZeneca PLC
• 7.4. Bayer AG
• 7.5. Danaher Corp.
• 7.6. Becton, Dickinson and Co.
• 7.7. Biomerieux S.A.
• 7.8. Bio-Rad Laboratories Inc.
• 7.9. Biotronik SE & Co. KG
• 7.10. Boehringer Ingelheim GmbH
• 7.11. F. Hoffmann-La Roche Ltd.
• 7.12. GlaxoSmithKline PLC
• 7.13. Novartis International AG
• 7.14. Pfizer Inc.
• 7.15. Sanofi S.A.
• 7.16. Siemens AG
• 7.17. Shionogi & Co., Ltd.
• 7.18. Sysmex Europe GmbH.
• 7.19. Teva Pharmaceutical Industries Ltd.
• 7.20. Watson's Personal Care Pte. Ltd.

LIST OF TABLES

• 1. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYE, 2020-2027 ($ MILLION)
• 2. GLOBAL BIOCHEMICAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 3. GLOBAL MICROSCOPIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 4. GLOBAL FLOW CYTOMETRIC URINARY TRACT INFECTIONMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

5. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION,

• 6. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
• 7. GLOBAL UNCOMPLICATED URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 8. GLOBAL NEUROGENIC BLADDER INFECTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 9. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 10. GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 11. GLOBAL HOME HEALTHCARE MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
• 12. GLOBAL URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
• 13. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 14. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2020-2027 ($ MILLION)
• 15. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
• 16. NORTH AMERICAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 17. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 18. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2020-2027 ($ MILLION)
• 19. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
• 20. EUROPEAN URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 21. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 22. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2020-2027 ($ MILLION)
• 23. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
• 24. ASIA-PACIFIC URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
• 25. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 26. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY TEST TYPE 2020-2027 ($ MILLION)
• 27. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY INDICATION, 2020-2027 ($ MILLION)
• 28. REST OF THE WORLD URINARY TRACT INFECTION MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL URINARY TRACT INFECTION MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL URINARY TRACT INFECTION MARKET BY SEGMENT, 2020-2027 (% MILLION)

• 3. RECOVERY OF GLOBAL URINARY TRACT INFECTION MARKET, 2020-2027 (%)
• 4. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY TEST TYPE, 2020 VS 2027 (%)
• 5. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY INDICATION, 2020 VS 2027 (%)
• 6. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY END-USER 2020 VS 2027 (%)
• 7. GLOBAL URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 8. GLOBAL BIOCHEMICAL URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 9. GLOBAL MICROSCOPIC URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 10. GLOBAL FLOW CYTOMETRIC URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 11. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 12. GLOBAL UNCOMPLICATED URINARY TRACT INFECTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 13. GLOBAL NEUROGENIC BLADDER INFECTIONS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 14. GLOBAL HOSPITALS AND CLINICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 15. GLOBAL HOME HEALTHCARE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 16. US URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 17. CANADA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 18. UK URINARY TRACT INFECTION AND MICROSCOPIC URINARY TRACT INFECTIONMARKET SIZE, 2020-2027($ MILLION)
• 19. FRANCE URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 20. GERMANY URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 21. ITALY URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 22. SPAIN URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 23. REST OF EUROPE URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 24. INDIA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 25. CHINA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 26. JAPAN URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 27. SOUTH KOREA URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 28. REST OF ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)
• 29. REST OF THE WORLD URINARY TRACT INFECTION MARKET SIZE, 2020-2027($ MILLION)